Nephrol Dial Transplant (2003) 18: 265-272
© 2003 European Renal Association-European Dialysis and Transplant Association
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats
Department of Medicine and Clinical Science Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
Background. An inflammatory process may be one of the critical factors that contribute to the development of diabetic nephropathy (DN). We reported previously that intercellular adhesion molecule-1 (ICAM-1) is up-regulated and promotes macrophage infiltration in the glomeruli of diabetic rats. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have recently been emphasized to have anti-inflammatory effects; inhibition of leukocyte adhesion and migration, independent of the cholesterol-lowering effect. The present study was designed to test the hypothesis that statins prevent the development of DN by pleiotropic effects.
Methods. Streptozotocin-induced diabetic rats were treated with cerivastatin (0.5 mg/kg body weight) or vehicle for 4 weeks. We analysed glomerular macrophage infiltration and ICAM-1 expression. We also evaluated major regulators of ICAM-1, activation of nuclear factor-kappa B (NF-
B) using electrophoretic mobility shift assay, and oxidative stress.
Results. Statin treatment reduced urinary albumin excretion (UAE) (2.96±0.18 vs 2.38±0.06; log10 UAE, P<0.05), glomerular size (12 150±329 vs 9963±307 µm2, P<0.05), and lowered blood pressure, compared with untreated diabetic rats. Immunohistochemistry revealed that macrophage infiltration and ICAM-1 expression in glomeruli were increased in diabetic rats and were inhibited by statin treatment. Renal NF-B activity, urinary excretion and renal deposition of 8-OHdG were increased in diabetic rats, and reduced by statin treatment.
Conclusion. Statin treatment prevented glomerular injury, independent of the cholesterol-lowering effects. Our findings suggest that the beneficial effect might be mediated by pleiotropic effects including an anti-inflammatory action through a reduction of oxidative stress, NF-B activation, ICAM-1 expression and macrophage infiltration in the early phase of DN.
Keywords: diabetic nephropathy; HMG-CoA reductase inhibitor; ICAM-1; macrophage; NF-B; oxidative stress
Correspondence and offprint requests to: Kenichi Shikata, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Email: shikata{at}md.okayama-u.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. L. S. Brookes, C. C. McGown, and C. S. Reilly Statins for all: the new premed? Br. J. Anaesth., July 1, 2009; 103(1): 99 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control Diabetes, March 1, 2008; 57(3): 714 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-M. Liang, H. Otani, Q. Zhou, Y. Tone, R. Fujii, M. Mune, S. Yukawa, and T. Akizawa Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2156 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ohga, K. Shikata, K. Yozai, S. Okada, D. Ogawa, H. Usui, J. Wada, Y. Shikata, and H. Makino Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-{kappa}B activation Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1141 - F1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tone, K. Shikata, D. Ogawa, S. Sasaki, R. Nagase, M. Sasaki, K. Yozai, H. Kataoka Usui, S. Okada, J. Wada, et al. Changes of gene expression profiles in macrophages stimulated by angiotensin II -- Angiotensin II induces MCP-2 through AT1-receptor Journal of Renin-Angiotensin-Aldosterone System, March 1, 2007; 8(1): 45 - 50. [Abstract] [PDF]
|
|
|
|
|
|
H. K. Usui, K. Shikata, M. Sasaki, S. Okada, M. Matsuda, Y. Shikata, D. Ogawa, Y. Kido, R. Nagase, K. Yozai, et al. Macrophage Scavenger Receptor-A-Deficient Mice Are Resistant Against Diabetic Nephropathy Through Amelioration of Microinflammation Diabetes, February 1, 2007; 56(2): 363 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Xu, L. Zeng, H. Peng, S. Chen, J. Jones, T.-L. Chew, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation Am J Physiol Renal Physiol, November 1, 2006; 291(5): F995 - F1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Chade, X. Zhu, O. P. Mushin, C. Napoli, A. Lerman, and L. O. Lerman Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia FASEB J, August 1, 2006; 20(10): 1706 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D'Amico Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S148 - S152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, and H. Koide Effect of Pitavastatin on Urinary Liver-Type Fatty Acid-Binding Protein Levels in Patients With Early Diabetic Nephropathy Diabetes Care, November 1, 2005; 28(11): 2728 - 2732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yozai, K. Shikata, M. Sasaki, A. Tone, S. Ohga, H. Usui, S. Okada, J. Wada, R. Nagase, D. Ogawa, et al. Methotrexate Prevents Renal Injury in Experimental Diabetic Rats via Anti-Inflammatory Actions J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3326 - 3338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mauro Vieira Jr, E. Mantovani, L. Tavares Rodrigues, H. Delle, I. L. Noronha, C. K. Fujihara, and R. Zatz Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1582 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Satoh, S. Fujimoto, Y. Haruna, S. Arakawa, H. Horike, N. Komai, T. Sasaki, K. Tsujioka, H. Makino, and N. Kashihara NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1144 - F1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zeng, H. Xu, T.-L. Chew, R. Chisholm, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh Simvastatin Modulates Angiotensin II Signaling Pathway by Preventing Rac1-Mediated Upregulation of p27 J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1711 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. DANESH and Y. S. KANWAR Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy FASEB J, May 1, 2004; 18(7): 805 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tonolo, P. Brizzi, M. G. Melis, G. Secchi, and M. Maioli About the pleiotropic effects of statins in human Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1234 - 1234. [Full Text] [PDF]
|
|